We take 23,000 breaths per day, and with each breath we inhale a combination of airborne chemicals – for example pollution, perfume, household sprays, inhaled medications for managing allergies and lung diseases such as asthma. However, as a society we are increasingly aware of the impact that such chemicals can have on our health. Regulators oblige the industries that develop and manufacture chemical products – including pharmaceuticals, agrichemicals, chemicals and consumer products – to carry out increasingly stringent risk assessments. But such risk assessments often require a large amount of animal trials, which are time-consuming, costly and unpopular. Another problem is that risk assessments are often binary – with either a “good” outcome or a “bad” one.

ImmuONE provides a solution – a cost-effective, multi-endpoint alternative which is more human-relevant and reduces animal testing, exploring various interpretations of a read-out.

We are experts in the lung’s immune system – in particular, the alveolar macrophages which are the first to respond when a chemical enters the respiratory system. Our services, products and experts can accurately predict the immune system’s response in the lungs.

Our unique in vitro models and multi-endpoint assessments deliver results spanning morphology, function and biochemistry to provide companies with clarity on the human health impact of their products.